Dorrigocin A
Dorrigocin A is an analog of Migrastatin (HY-121452). Dorrigocin A can inhibit the carboxymethyltransferase involved in Ras processing and reverse the morphology of ras-transformed NIH/3T3 cells. Dorrigocin A is promising for research of anti-cancer and anti-arthritis agents.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 158446-29-8
- Formel: C27H41NO8
- Molecular Weight:507.62
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
>100 μM
Compound: 4a, dorrigocin A
|
Cytotoxicity against human mouse 4T1 cells
Cytotoxicity against human mouse 4T1 cells
|
[PMID: 18684620] |
| 4T1 | IC50 |
>100 μM
Compound: 4a, dorrigocin A
|
Inhibition of cell migration of mouse 4T1 cells after 4 days by scratch wound healing assay
Inhibition of cell migration of mouse 4T1 cells after 4 days by scratch wound healing assay
|
[PMID: 18684620] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: 4a, dorrigocin A
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 18684620] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: 4a, dorrigocin A
|
Inhibition of human MDA-MB-231 cell migration after 4 days by scratch wound healing assay
Inhibition of human MDA-MB-231 cell migration after 4 days by scratch wound healing assay
|
[PMID: 18684620] |
Chemical Information
-
CAS. Nr. 158446-29-8
-
Molecular Weight 507.62
-
Formel C27H41NO8
-
SMILES
O=C(O)/C=C/CC/C=C/[C@H](OC)[C@@H](O)[C@H](C)/C=C(C)/[C@H](O)[C@H](C)C(CCCC(C1)CC(NC1=O)=O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)